Cargando…
Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver
Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613674/ https://www.ncbi.nlm.nih.gov/pubmed/28966992 http://dx.doi.org/10.1002/hep4.1012 |
_version_ | 1783266305605894144 |
---|---|
author | Feriod, Colleen N. Gustavo Oliveira, Andre Guerra, Mateus T. Nguyen, Lily Mitchell Richards, Kisha Jurczak, Michael J. Ruan, Hai‐Bin Paulo Camporez, Joao Yang, Xiaoyong Shulman, Gerald I. Bennett, Anton M. Nathanson, Michael H. Ehrlich, Barbara E. |
author_facet | Feriod, Colleen N. Gustavo Oliveira, Andre Guerra, Mateus T. Nguyen, Lily Mitchell Richards, Kisha Jurczak, Michael J. Ruan, Hai‐Bin Paulo Camporez, Joao Yang, Xiaoyong Shulman, Gerald I. Bennett, Anton M. Nathanson, Michael H. Ehrlich, Barbara E. |
author_sort | Feriod, Colleen N. |
collection | PubMed |
description | Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation. Here we show that the type 1 isoform of the inositol 1,4,5‐trisphosphate receptor (InsP(3)R1) specifically links ER calcium release to mitochondrial calcium signaling and lipid droplet formation in hepatocytes. Moreover, liver‐specific InsP(3)R1 knockout mice have impaired mitochondrial calcium signaling, decreased hepatic triglycerides, and reduced lipid droplet formation and are resistant to the development of fatty liver. Patients with nonalcoholic steatohepatitis, the most malignant form of fatty liver, have increased hepatic expression of InsP(3)R1, and the extent of ER–mitochondrial colocalization correlates with the degree of steatosis in human liver biopsies. Conclusion: InsP(3)R1 plays a central role in lipid droplet formation in hepatocytes, and the data suggest that it is involved in the development of human fatty liver disease. (Hepatology Communications 2017;1:23–35) |
format | Online Article Text |
id | pubmed-5613674 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56136742018-02-01 Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver Feriod, Colleen N. Gustavo Oliveira, Andre Guerra, Mateus T. Nguyen, Lily Mitchell Richards, Kisha Jurczak, Michael J. Ruan, Hai‐Bin Paulo Camporez, Joao Yang, Xiaoyong Shulman, Gerald I. Bennett, Anton M. Nathanson, Michael H. Ehrlich, Barbara E. Hepatol Commun Original Articles Fatty liver is the most common type of liver disease, affecting nearly one third of the U.S. population and more than half a billion people worldwide. Abnormalities in endoplasmic reticulum (ER) calcium handling and mitochondrial function each have been implicated in abnormal lipid droplet formation. Here we show that the type 1 isoform of the inositol 1,4,5‐trisphosphate receptor (InsP(3)R1) specifically links ER calcium release to mitochondrial calcium signaling and lipid droplet formation in hepatocytes. Moreover, liver‐specific InsP(3)R1 knockout mice have impaired mitochondrial calcium signaling, decreased hepatic triglycerides, and reduced lipid droplet formation and are resistant to the development of fatty liver. Patients with nonalcoholic steatohepatitis, the most malignant form of fatty liver, have increased hepatic expression of InsP(3)R1, and the extent of ER–mitochondrial colocalization correlates with the degree of steatosis in human liver biopsies. Conclusion: InsP(3)R1 plays a central role in lipid droplet formation in hepatocytes, and the data suggest that it is involved in the development of human fatty liver disease. (Hepatology Communications 2017;1:23–35) John Wiley and Sons Inc. 2016-11-11 /pmc/articles/PMC5613674/ /pubmed/28966992 http://dx.doi.org/10.1002/hep4.1012 Text en © 2016 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Feriod, Colleen N. Gustavo Oliveira, Andre Guerra, Mateus T. Nguyen, Lily Mitchell Richards, Kisha Jurczak, Michael J. Ruan, Hai‐Bin Paulo Camporez, Joao Yang, Xiaoyong Shulman, Gerald I. Bennett, Anton M. Nathanson, Michael H. Ehrlich, Barbara E. Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
title | Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
title_full | Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
title_fullStr | Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
title_full_unstemmed | Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
title_short | Hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
title_sort | hepatic inositol 1,4,5 trisphosphate receptor type 1 mediates fatty liver |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5613674/ https://www.ncbi.nlm.nih.gov/pubmed/28966992 http://dx.doi.org/10.1002/hep4.1012 |
work_keys_str_mv | AT feriodcolleenn hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT gustavooliveiraandre hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT guerramateust hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT nguyenlily hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT mitchellrichardskisha hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT jurczakmichaelj hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT ruanhaibin hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT paulocamporezjoao hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT yangxiaoyong hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT shulmangeraldi hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT bennettantonm hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT nathansonmichaelh hepaticinositol145trisphosphatereceptortype1mediatesfattyliver AT ehrlichbarbarae hepaticinositol145trisphosphatereceptortype1mediatesfattyliver |